Objective
Current epilepsy therapies, based on mediating excitation or inhibition have no impact on disease progression and are ineffective in over 30% of patients, demonstrating the urgent need for therapies with different mechanisms of action. An exciting concept is that increased hyperexcitability states and network changes are caused and maintained by a sustained glial activation.The ATP-gated P2X7 receptor (P2X7R), a gatekeeper of inflammation, has recently emerged as a promising target for epilepsy, showing anticonvulsant and disease-modifying properties in animal models. To bring P2X7R further towards a clinical application, however, important gaps in our understanding must be filled. Evidence for ATP release in the brain during seizures is currently lacking, the cell types involved in pathological P2X7R activation must be determined, and whether results from rodent models can be replicated in human tissue must be tested. Recent technical advances now bring the answers to these questions within reach. EpiPur brings together a team of experts in purinergic signalling, industrial partners specialised in the development of P2X7R antagonists and epilepsy clinicians. Biosensors will be used to record ATP in vivo with high sensitivity and temporal resolution; new transgenic mouse lines will be used to elucidate the subcellular expression and cell-specific disease contribution of P2X7R. Newly developed P2X7R antagonists will be tested in brain tissue resected from epilepsy patients. This highly interdisciplinary and intersectoral approach will add a significant contribution to the understanding of neuroinflammatory processes in disorders of the CNS. Further, the skills acquired during the research project, the excellent training record of the supervisor and host institution and the outstanding resources for learning and development available at RCSI will give me the tools necessary to achieve research independence.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- engineering and technology electrical engineering, electronic engineering, information engineering electronic engineering sensors biosensors
- medical and health sciences basic medicine neurology epilepsy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2 DUBLIN
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.